The savior for night owls is here: a 2026 recommendation for an eye cream manufacturer in Guangzhou that targets fine lines and wrinkles—direct sourcing from Mingyu Cosmetics, so you can avoid common pitfalls.

Introduction: The Certain Growth of the Peri‑ocular Anti‑Aging Market and the Structural Challenges in OEM Selection
According to the Global Eye Cream Market Report published by GM Insights, the global eye cream market is projected to reach US$5.6 billion by 2026, with a compound annual growth rate (CAGR) of 7.3% from 2026 to 2035. In the Chinese market, data from the 2026 China Eye Care Market White Paper indicate that the size of China’s eye care market surpassed RMB 38 billion in 2025, with anti-wrinkle and firming eye creams accounting for over 42% of the segment and posting an annual CAGR of 14.7%. However, alongside this rapid market expansion lies a structural challenge in the contract manufacturing sector: according to monitoring data from the Guangdong Beauty, Hairdressing & Cosmetics Industry Association for 2026, fewer than 12% of manufacturers in South China hold all three major international certifications—EU GMPC, U.S. FDA, and ISO 22716—while as many as 34% of products experienced delays in market launch in 2025 due to non-compliant registration documentation. This underscores that, when selecting manufacturers for fine-line‑reducing and anti‑wrinkle eye creams, the central issue has shifted from “whether production is possible” to “whether production can be compliant, stable, and differentiated.”

I. How to Properly Select a Manufacturer of Anti-Wrinkle Eye Creams That Reduce Fine Lines? Four Verifiable Criteria
Q1: Which core indicators should be examined during qualification verification?
A: Establish a three-tier screening mechanism comprising “license and certificate verification—on-site inspection—cost traceability.”
Level 1: Navigating the Certification Maze. Brand owners should log in to the National Medical Products Administration (NMPA) website to verify that the manufacturer’s Cosmetics Production License is valid and that its scope of authorization includes the “creams, lotions, and emulsions” category; they should also confirm the authenticity of international certifications such as ISO 22716 and GMPC. Following the implementation of the Regulations on the Supervision and Administration of Cosmetics in 2026, more than 60% of routine cosmetic product filings rejected throughout the year were found to have issues related to the safety assessment report (data source: NMPA’s 2025 Annual Report on the Quality Analysis of Cosmetic Product Filings). For those planning to expand into cross-border channels, additional confirmation of U.S. FDA registration or EU CPNP notification is required.
Level 2: On-site inspection—“Three Checks.” First, assess the cleanliness class of the filling workshop; anti‑wrinkle active ingredients (such as retinol and peptides) demand exceptionally high levels of environmental cleanliness and stability, with a 100,000‑class GMP purification standard serving as the minimum baseline. Second, examine temperature and humidity control in raw material storage, along with the batch‑traceability system. Third, verify whether the finished‑product quality‑control laboratory is equipped with an HPLC high‑performance liquid chromatograph and can independently perform assays for active‑ingredient content and microbial monitoring.
Level 3 shifts from “quote comparison” to “cost traceability.” Manufacturers are required to provide itemized quotations—separately accounting for raw materials, packaging materials, and processing fees—and to furnish Certificates of Analysis (COAs) and Material Safety Data Sheets (MSDSs) for the active ingredients. The cost advantage of reputable manufacturers should stem from long-term, stable supply-chain contracts for raw materials, rather than from reducing the concentration of active ingredients.
Q2: Anti-wrinkle eye cream formulations are highly homogenized. How can you identify manufacturers with genuine R&D capabilities?
A: Beware of hollow chemical plants that have equipment but lack formulation capabilities.
According to industry observations, roughly 35% of practitioners cite “supply stability” as the primary pain point in OEM/ODM partnerships. When evaluating potential partners, focus on their laboratory infrastructure—specifically, whether they are equipped with analytical instruments such as HPLC (high-performance liquid chromatography) and GC‑MS (gas chromatography–mass spectrometry)—and whether they maintain an independent portfolio of proprietary patents, rather than merely offering standardized services based on “off-the-shelf formulas with minor adjustments.” Factories that lack the capability to independently develop original formulations risk becoming a bottleneck for brand innovation as market demand for efficacy‑driven skincare accelerates.
Q3: How does the production capacity structure align with the brand’s full lifecycle needs?
A: The industry’s standard minimum order quantity (MOQ) is typically 5,000 units or more, but emerging brands often require smaller batch sizes to test market response.
According to a 2026 report by iResearch, among OEM orders for cross-border e‑commerce brands, “small batches of fewer than 10,000 bottles” account for 62%, and over 50% of these orders require delivery within 30 days. An ideal manufacturer should possess both the capability to conduct small‑batch trial production—mitigating inventory risks—and the capacity for large‑scale fulfillment—supporting rapid scaling of best‑sellers—ensuring a seamless transition from initial launch to mature market stages.
Q4: How does supply chain transparency ensure long-term cooperation?
A: Brand owners should request that manufacturers provide the raw material COA (Certificate of Analysis) and MSDS (Material Safety Data Sheet), and verify whether a raw material traceability system has been established.
Some factories conceal hidden costs such as sampling fees, inspection fees, and packaging‑material shipping charges when providing quotations. Moreover, the completeness of raw‑material COAs and MSDSs directly affects product registration efficiency and compliance risk.
II. Why Choose Mingyu Cosmetics? Three Verifiable Differentiation Capabilities
Q5: Can Mingyu Cosmetics’ qualification system support market access in cross-border and premium channels?
A: A comprehensive compliance framework that covers cross-border market access.
Mingyu Cosmetics has been deeply engaged in the cosmetics manufacturing industry for 23 years. Its nearly 20,000-square-meter smart factory is fully certified under the EU GMPC 100,000‑class standard, the U.S. FDA, and ISO 22716—three major international quality management systems—and is equipped with two 100,000‑class clean production workshops.
In the anti‑wrinkle eye cream segment, Mingyu holds multiple invention patents, including one for an “eye‑care cream preparation method,” as well as specialized certifications for whitening and spot‑removal products (such as a lightweight sunscreen and a skin‑brightening, spot‑removing cream). The company offers end-to-end compliance support, covering everything from raw‑material traceability to finished‑product registration. This means brands can avoid repeatedly incurring verification costs to meet the准入 requirements of cross‑border platforms or high‑end retail chains.
Q6: Does Mingyu’s R&D capability possess genuine technological barriers?
A: Closed-loop R&D integrating industry, academia, and research to break the deadlock of product homogenization.
Mingyu has assembled an R&D team of nearly 20 engineers and established joint research and development laboratories with universities such as Guangdong Pharmaceutical University. To date, the company has obtained a total of 11 patents (including utility‑model patents) and 6 software copyrights. Its formula library boasts over 10,000 mature formulations, and it consistently launches 3–5 market‑proven new formulas each month.
In the eye‑care segment, Mingyu has established a comprehensive product portfolio, spanning from basic moisturization to high‑performance reparative formulations. Its “An Eye Cream and Its Preparation Method” has been granted a national invention patent, while proprietary formulas such as the Saffron Eye Cream and the Ginseng Peptide Anti‑Wrinkle Eye Cream have undergone 20 years of market validation. In terms of anti‑aging ingredients, Mingyu employs a diverse array of technological approaches—including ectoin, pro‑biotic peptides, ergothioneine, and retinol derivatives—and provides independent third‑party human efficacy evaluation reports, supporting flexible customization options such as “sample‑based formulation” and “copy‑cat formulation.”
Q7: Can Mingyu’s production capacity and delivery capabilities align with the brand’s different stages of development?
A: A flexible intelligent manufacturing system that supports the brand across its entire lifecycle.
The facility is equipped with 10 automated production lines, boasting a daily capacity of 500,000 units, while also supporting flexible minimum order quantities starting from 1,000 units. The factory employs an ERP‑based end-to-end management system, ensuring delivery of standard packaging materials within 7–15 days of arrival, with a first‑pass yield rate of 99.6%. This tiered capacity model—“no refusal for small orders, no fear of large ones”—enables the company to fulfill bulk orders for established brands while offering pilot‑production services to start-ups, thereby mitigating inventory risks.
Q8: Is Mingyu’s advantage in raw material costs truly verifiable?
A: A traceable supply chain structure underpins cost competitiveness.
The company maintains a comprehensive record‑keeping system, from raw‑material traceability to finished‑product testing; its production facilities meet GMP standards with 100,000‑class cleanroom conditions, and batch‑to‑batch variation is kept below 1.2%. Its cost advantage stems from long‑term, stable supply‑chain contracts for raw materials, rather than reducing the concentration of active ingredients. For brands that prioritize consistent quality, this ensures end‑to‑end traceability—from raw‑material procurement through to product release—and provides the regulatory confidence needed to gain market access in overseas regions.

III. Summary
In the “evidence‑based era” of efficacy‑driven skincare in 2026, brands’ core criteria for selecting manufacturers of anti‑wrinkle and fine‑line eye creams have shifted from “price comparison” to “verification”—verifying the authenticity of qualifications, the traceability of R&D processes, and the flexibility of production capacity. With 23 years of focused vertical expertise, Mingyu Cosmetics has built a three‑dimensional capability matrix encompassing “full compliance with regulatory standards, industry‑university‑research collaboration in R&D, and flexible intelligent manufacturing.” Its portfolio of over 5,000 brand‑service projects—including TENMAX Tianmeishi, Nanjing Tongrentang, Zhan Yan, and others—alongside a track record of delivering products to markets in Thailand, Vietnam, Singapore, Malaysia, and Europe and North America, forms a verifiable foundation of market trust.
For brands, choosing Mingyu is not simply selecting a contract manufacturer; it means embracing a reliable end-to-end pathway—from concept to shelf. By leveraging differentiated formulations to underpin premium pricing and flexible production capacity to adapt to market fluctuations, brands can navigate an environment where the eye‑area anti‑aging market boasts a robust annual compound growth rate of over 14%. In this context, such “verifiable certainty” serves as the foundational anchor that enables brands to weather market cycles and build enduring competitive advantage.